Search page

A randomized, double-blind, phase 2a study of covalent Bruton’s tyrosine kinase inhibitor TAS5315 in patients with chronic spontaneous urticaria with an inadequate response to H1-antihistamines

A retrospective analysis of patients with chronic spontaneous urticaria in treatment with Omalizumab conducted in Brescia

Artificial intelligence-assisted prediction of olfactory disorders in patients with chronic rhinosinusitis

Assessment of local nasal IgE in patients with suspected dual allergic rhinitis before and after nasal allergen provocation – presentation of 6 cases

Being attack-free is associated with improved quality of life for patients with hereditary angioedema treated with garadacimab: Post hoc analysis from the pivotal Phase 3 (VANGUARD) study

Biologics and rhinosinusitis with and without nasal polyps

Characterization of the clinical phenotype of patients with CSU treated with cyclosporin alone or combined with omalizumab

Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Chronic rhinosinusitis among young adults is strongly associated with atopy and signs of type-1 inflammation

Clinical Effectiveness of Tezepelumab on Upper and Lower Airway Symptoms in Patients with Asthma and Co-morbid Nasal Polyposis

Clinical effects of dupilumab in patients with rhinosinusitis, nasal polyposis, and severe uncontrolled asthma with t2 phenotype, after 12 months of treatment

Construction of prediction model for olfactory dysfunction improvement in patient with chronic rhinosinusitis after endoscopic sinus surgery

Could there be an infusion reaction with docetaxel and an IgE-mediated reaction with pertuzumab in the same case? 3-bag, 12-step successful desensitization protocol presentation with pertuzumab

Doxycycline therapy reduced local nasal inflammation and promoted wound healing after FESS in Chronic Rhinosinusitis patients

Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis

Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis

Efficacy and safety of therapy with omalizumab in children with chronic spontaneous urticaria

Efficacy of Re-treatment with Omalizumab in Adults with Chronic Spontaneous Urticaria who Relapsed after Treatment Withdrawal

Efficacy of two years of treatment with anti-IL-5/R therapy for reduction in use of oral glucocorticoids in patients with eosinophilic granulomatosis with polyangiitis

Evaluation of the tolerability of the administration of subcutaneous immunotherapy in a cluster schedule, in patients with rhinoconjunctivitis and/or asthma with sensitization to Olea europaea with or without sensitization to grasses

Features of chronic spontaneous urticaria in patients with atopic comorbidities: Results from CURE, the chronic urticaria registry

First clinical practice of using biologic therapy with dupilumab in combination with allergen-specific immunotherapy in a patient with severe atopic dermatitis and bronchial asthma

Frequency and impact of chronic rhinosinusitis on allergic rhinitis: a retrospective multicenter cohort study with long term follow-up

INFANT WITH PERSISTENT VOMITING, BLOODY DIARRHEA AND NON-IgE MEDIATED FOOD ALLERGY WITH GOOD RESPONSE TO AMINOACIDS FORMULA WITH SYNBIOTICS

Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis

Local nasal inflammation and postoperative wound healing is improved by postoperative doxycycline therapy after FESS in Chronic Rhinosinusitis patients

Long-term prophylaxis with first line therapies in patients with hereditary angioedema with C1 inhibitor deficiency, real-life experience

Nasal microbiome in chronic rhinosinusitis

Occupational sensitisation to Chrysonilia sitophila in an asthmatic patient with nasal polyposis

Pathological Characteristics of Chronic Rhinosinusitis and Their Association with Urbanization: A Retrospective Study Based on Whole-Slide Scanning Using Artificial Intelligence

Platycodon D protects human nasal epithelial cells from pyroptosis through the Nrf2/HO-1/ROS signaling cascade in chronic rhinosinusitis

Predictive model for postoperative unrecovered olfactory function in chronic rhinosinusitis patients with olfactory disorder

Reduction in Weekly Urticaria Activity Score (UAS7) With Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 Dose-Ranging Study

SPOTLIGHT: A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihis

The Influence of Dupilumab on the Nasal and Gastrointestinal Microbiome in Diffuse Type 2 Chronic Rhinosinusitis

The impact of secretory IgA on nasal microbiome control and its link to the development of chronic rhinosinusitis

Use of dupilumab in two pregnant women with nasal polyposis and severe persistent asthma: two case reports

A Regulatory Risk haplotype in HLA-DQ region regulates antigen presentation of monocyte in Type 2 inflammation in chronic rhinosinusitis with nasal polyps

A patient-centric approach to chronic rhinosinusitis with nasal polyps (CRSwNP): developing tools to improve disease management and outcomes

A step towards standardized Clinical Remission Criteria for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): insights from a real-life study

Anti-thymic stromal lymphopoietin CM326 for uncontrolled chronic rhinosinusitis with nasal polyps: a randomized, double-blind, placebo-controlled phase 1b/2a trial

Association between olfactory function, nasal polyp score, nasal obstruction and quality of life in CRSwNP patients treated with dupilumab

Challenges in Biologics for Chronic Rhinosinusitis with Nasal Polyps

Clinical Implication of Neutrophil Phenotypes in Chronic Rhinosinusitis With Nasal Polyps

Correlation of chronic rhinosinusitis and lung function in allergy patients with chronic cough

CosMx™ single cell spatial imaging identifies changes in spatial cell communication in chronic rhinosinusitis with nasal polyps following anti – IL-5 treatment

Distribution of Baseline Type 2 Inflammation Characteristics in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Biologic Clinical Trials: A Comparative Assessment

Dupilumab Treatment is Associated with Clinical Improvement and a Shift towards a health-associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis

Dupilumab alleviates the abnormal differentiation of club cells induced by IL-13 in chronic rhinosinusitis with nasal polyps

Early Responders within One Month of Dupilumab Treatment for Chronic Rhinosinusitis with Nasal Polyps

Effect of anti IL-5/IL-5Rα biological treatment on tissue eosinophil subpopulations in patients affected by Chronic Rhinosinusitis with Nasal Polyp

Effects of Dupilumab on Eosinophil Subpopulations and Inflammation in Chronic Rhinosinusitis with Nasal Polyps

Efficacy of Dupliuzumab in the treatment of atopic dermatitis complicated by chronic rhinosinusitis with nasal polyps

Emerging Biologic Use May Reduce the Need for Corticosteroid Treatment and Surgery for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in France, Germany, Italy, Spain and the UK

Eosinophilic Chronic Rhinosinusitis with Nasal Polyps : Current Perspective

Hippo-YAP inhibits the autophagic degradation of Cyclin D1 in chronic rhinosinusitis with nasal polyps

Improvement in Olfactory Training for Postoperative Olfactory Dysfunction in Chronic Rhinosinusitis with Nasal Polyps

Longitudinal Assessment of Dupilumab’s Therapeutic Effects in Chronic Rhinosinusitis with Nasal Polyps

PROMs Improvement Effects of Biologics in Chronic Rhinosinusitis with Nasal Polyps Patients: Real-life Experience

Performance of 5 item and 22 item sino-nasal outcome tests in response to dupilumab in chronic rhinosinusitis with nasal polyps

Postoperative Anti-IgE Therapy for Chronic Rhinosinusitis with Nasal Polyps and Asthma: Efficacy and Prognostic Factors

REALITI-N: First Ambidirectional Cohort Study Evaluating Real-World Mepolizumab Use in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Real-Life Effectiveness of Mepolizumab and Omalizumab in Sever Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Prospective Study

Real-Life Effectiveness of Monoclonal Antibody Therapy in Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Prospective Study

Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years

SNOT-22 and olfactory perception in Chronic Rhinosinusitis with Nasal Polyps: A Retrospective Observational Study

Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 trial

The Clinical Characteristics and Inflammatory Endotypes of Chronic Rhinosinusitis with Nasal Polyps in Southern China: A Multi-Center, Cross Section study

The Relationship Between Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Serum Mas-Related G-Protein Coupled Receptor-X2 (MRGPRX2) Level

The Role of Rho GTPase Signaling on Epithelial-Mesenchymal Transition and Inflammation of Chronic Rhinosinusitis with Nasal Polyp

The correlation between chronic rhinosinusitis with/without nasal polyp and chronic kidney disease: a longitudinal follow-up study

The multi-omics single-cell landscape of sinus mucosa in uncontrolled severe chronic rhinosinusitis with nasal polyps

Understanding and managing Chronic Rhinosinusitis with Nasal Polyps

Unveiling the Prevalence and Impact of Silent Rhinovirus Infection in Chronic Rhinosinusitis with Nasal Polyps

ANCHOR-1 and 2 Study Design: Replicate Phase 3 Randomised, Double-Blind, Placebo-Controlled Studies of the Efficacy and Safety of Depemokimab in Patients with Chronic Rhinosinusitis with Nasal Polyps

Allergen Immunotherapy decreases biologicals use in allergic rhinitis with chronic rhinosinusitis with nasal polyps (CRSwNP)

Baseline Disease Characteristics Among Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma in the Global AROMA Registry

Characteristics of patients with chronic rhinosinusitis with nasal polyps and allergic rhinitis enrolled in the global AROMA registry

Chronic rhinosinusitis with nasal polyposis: an old problem with a new solution

Clinical and Treatment Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps by Treating Physician Specialty: Results from an EU Chart Review Study

Clinical improvement with mepolizumab after endoscopic nasal polyposis surgery in a patient with polyposis

Dual monoclonal antibody therapy in a patient with chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma: a case report and proteome analysis

Dupilumab Restores Barrier Function of Nasal Epithelial Cells and Decreases Type-2 Inflammatory Markers in Chronic Rhinosinusitis with Nasal Polyps

Effect of Dupilumab on Radiological Remission in Patients with Chronic Rhinosinusitis with Nasal Polyp: A step Toward Clinical Remission

Effectiveness and Safety of Dupilumab in patients with chronic rhinosinusitis with nasal polyps After One Year of Therapy: Results from a real-world non-interventional study in Germany (ProGNOSE)

Efficacy of Omalizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps and Association with Local Immunoglobulin E

Enhanced Production of CEACAM5 And Its Association With Increased Plasma Cell Infiltration In Chronic Rhinosinusitis With Nasal Polyps

Evaluation of Early Real-World Efficacy and Safety of Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis Through a Multidisciplinary Approach

Improved Quality of Life, Early Symptom Control and Reduced Surgery with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Results from the SYNAPSE Study

Initiation of dupilumab led to reduced use of corticosteroids and antibiotics over 12 months in patients with chronic rhinosinusitis with nasal polyps treated in US real world practice

Mental health, sexual functionality, quality of life, and patient experiences with chronic rhinosinusitis with nasal polyps at UNIMEQ-ORL in Bogotá, Colombia, 2022-2024: a mixed-methods study

Nasal polyp CD62Llow eosinophils as a prognostic biomarker of chronic rhinosinusitis with nasal polyp severity and predictive biomarker of mepolizumab and dupilumab response

Proteomic analysis identifies patients with chronic rhinosinusitis with nasal polyps who are responders and non-responders to benralizumab (NAPPREB study)

Real-world effectiveness of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is independent of comorbidities, sinus surgery history and level of type 2 inflammation: Findings from CHRINOSOR

SLC27A2 marks lipid peroxidation in nasal epithelial cells driven by type 2 inflammation in chronic rhinosinusitis with nasal polyps

Tezepelumab reduces OCS use and improves sino-nasal symptoms in OCS-dependent patients with severe asthma and comorbid chronic rhinosinusitis (overall and with nasal polyps): results from the phase 3b WAYFINDER study

The impact of intranasal corticosteroids on exhaled nitric oxide in chronic eosinophilic rhinosinusitis with nasal polyposis after surgery

The role of anosmia in predicting biologic responsiveness for Chronic Rhinosinusitis with Nasal Polyposis

Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT)

Dupilumab-induced skin reaction in a patient with severe asthma and chronic rhinosinusitis with nasal polyposis and without prior skin conditions

Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps overall and in patients with and without co-morbid asthma: results from the phase 3 WAYPOINT study

Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma Experience Early and Sustained Benefit with Depemokimab in the Randomised, Double-Blind, Parallel-Group, Replicate ANCHOR-1/2 Studies

Sequence of improvements in objective and patient-reported outcomes with dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps: Analysis of the SINUS-52 study

Study of olfaction in patients with chronic rhinosinusitis with nasal polyposis undergoing Mepolizumab treatment

Modulation of eosinophilic and neutrophilic inflammation in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab, assessed by nasal cytology and biopsy histology

Real-Life effectiveness of a Cohort of Patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Concomitant Moderate Persistent Asthma Treated with Dupilumab

Welcome

Only match titles

What are you looking for?

Knowledge Hub

Website

Only match titles

What are you looking for?

Knowledge Hub

Event Resources

Covid-19

Guidelines

Position Papers

Website

Sessions